Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.78 |
| ▸ | POLB | P06746 | 2/20 | 0.78 |
| ▸ | RAB9A | P51151 | 1/20 | 0.78 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.62 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | CASP1 | P29466 | 2/20 | 0.56 |
| ▸ | CASP7 | P55210 | 1/20 | 0.56 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.55 |
| ▸ | ESR1 | P03372 | 5/20 | 0.55 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.52 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30743 | 0.88 | NPC1 (1.00) | NPC1POLBRAB9ADYRK1AMCL1 | |
| SCHEMBL29757180 | 0.88 | NPC1 (1.00) | NPC1POLBRAB9ADYRK1AMCL1 | |
| SCHEMBL4142572 | 0.88 | NPC1 (0.59) | NPC1POLBRAB9ADYRK1AMCL1 | |
| SCHEMBL22269645 | 0.85 | ALDH1A1 (0.72) | NPC1POLBRAB9ADYRK1AMCL1 | |
| SCHEMBL30592751 | 0.85 | NPC1 (0.84) | NPC1POLBRAB9ADYRK1AMCL1 | |
| SCHEMBL443618 | 0.85 | NPC1 (0.84) | NPC1POLBRAB9ADYRK1AMCL1 | |
| SCHEMBL12075055 | 0.85 | NPC1 (0.84) | NPC1POLBRAB9ADYRK1AMCL1 | |
| SCHEMBL112289 | 0.84 | ALDH1A1 (0.70) | NPC1POLBRAB9ADYRK1AMCL1 | |
| SCHEMBL30340866 | 0.83 | NPC1 (0.81) | NPC1POLBRAB9ADYRK1AMCL1 | |
| SCHEMBL21160821 | 0.83 | NPC1 (0.81) | NPC1POLBRAB9ADYRK1AMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108318462-A | Fluorescent probe molecule and its fluorescence membrane sensor and preparation method and application for pH detections | 重庆三峡学院 | 2018-07-24 | — | — | CN | claimed |
| CN-105636953-B | 1,4 dibasic pyridyl derivatives and its purposes for treating the illness related to SMN shortages | 诺华股份有限公司 | 2018-01-02 | — | — | CN | claimed |
| CN-1823046-A | Phenyl quinolines and their use as estrogen receptor modulators | WYETH CORP (US) | 2006-08-23 | — | — | CN | claimed |
| CN-108318462-A | Fluorescent probe molecule and its fluorescence membrane sensor and preparation method and application for pH detections | 重庆三峡学院 | 2018-07-24 | — | — | CN | disclosed |
| CN-105636953-B | 1,4 dibasic pyridyl derivatives and its purposes for treating the illness related to SMN shortages | 诺华股份有限公司 | 2018-01-02 | — | — | CN | disclosed |
| CN-102887891-B | N4-phenyl-quinazoline-4-sulfonamide derivatives and related compound | ARRAY BIOPHARMA INC. (US) | 2016-03-09 | — | — | CN | disclosed |
| US-9120749-B2 | Quinoline derivatives and MELK inhibitors containing the same | ONCOTHERAPY SCIENCE, INC. (JP) | 2015-09-01 | — | — | US | disclosed |
| US-9120749-B2 | Quinoline derivatives and MELK inhibitors containing the same | ONCOTHERAPY SCIENCE, INC. (JP) | 2015-09-01 | — | — | US | disclosed |
| US-9120749-B2 | Quinoline derivatives and MELK inhibitors containing the same | ONCOTHERAPY SCIENCE, INC. (JP) | 2015-09-01 | — | — | US | disclosed |
| US-20130217671-A1 | QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2013-08-22 | — | — | US | disclosed |
| US-20130217671-A1 | QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2013-08-22 | — | — | US | disclosed |
| US-20130217671-A1 | QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2013-08-22 | — | — | US | disclosed |
| CN-103153063-A | Quinoline derivatives and MELK inhibitors containing the same | ONCOTHERAPY SCIENCE INC | 2013-06-12 | — | — | CN | disclosed |
| EP-2597955-A1 | QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | OncoTherapy Science, Inc. (JP) | 2013-06-05 | — | — | EP | disclosed |
| CN-102887891-A | N4-phenyl-quinaz0line-4 -amine derivatives and related compounds | ARRAY BIOPHARMA INC | 2013-01-23 | — | — | CN | disclosed |
| WO-2012016082-A1 | QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-02-02 | — | — | WO | disclosed |
| CN-101906072-A | 3-phenylquinoline compounds as well as preparation method and application thereof | SHANGHAI INST MATERIA MEDICA | 2010-12-08 | — | — | CN | disclosed |
| CN-101356171-A | N4-phenyl-quinazolin-4-amine derivatives and related compounds as ERBBI type receptor tyrosine kinase inhibitors for the treatment of proliferative diseases | ARRAY BIOPHARMA INC (US) | 2009-01-28 | — | — | CN | disclosed |
| CN-1823046-A | Phenyl quinolines and their use as estrogen receptor modulators | WYETH CORP (US) | 2006-08-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217671-A1 | QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | MELK, NADK, NEK1 | NPC1 1911/4885POLB 2238/4885RAB9A 1502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.